|
1
|
Gustafsson BI, Kidd M, Chan A,
Malfertheiner MV and Modlin IM: Bronchopulmonary neuroendocrine
tumors. Cancer. 113:5–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dresler CM, Ritter JH, Patterson GA, Ross
E, Bailey MS and Wick MR: Clinical-pathologic analysis of 40
patients with large cell neuroendocrine carcinoma of the lung. Ann
Thorac Surg. 63:180–185. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raman V, Jawitz OK, Yang CJ, Tong BC,
D'Amico TA, Berry MF and Harpole DH Jr: Adjuvant therapy for
patients with early large cell lung neuroendocrine cancer: A
National Analysis. Ann Thorac Surg. 108:377–383. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Le Treut J, Sault MC, Lena H, Souquet PJ,
Vergnenegre A, Le Caer H, Berard H, Boffa S, Monnet I, Damotte D
and Chouaid C: Multicentre phase II study of cisplatin-etoposide
chemotherapy for advanced large-cell neuroendocrine lung carcinoma:
the GFPC 0302 study. Ann Oncol. 24:1548–1552. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Niho S, Kenmotsu H, Sekine I, Ishii G,
Ishikawa Y, Noguchi M, Oshita F, Watanabe S, Nakajima R, Tada H and
Nagai K: Combination chemotherapy with irinotecan and cisplatin for
large-cell neuroendocrine carcinoma of the lung: A multicenter
phase II study. J Thorac Oncol. 8:980–984. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xia L, Wang L, Zhou Z and Han S: Treatment
outcome and prognostic analysis of advanced large cell
neuroendocrine carcinoma of the lung. Sci Rep. 12:165622022.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheng Y, Han L, Wu L, Chen J, Sun H, Wen
G, Ji Y, Dvorkin M, Shi J, Pan Z, et al: Effect of First-Line
Serplulimab vs Placebo Added to Chemotherapy on Survival in
Patients With Extensive-Stage Small Cell Lung Cancer: The
ASTRUM-005 Randomized Clinical Trial. JAMA. 328:1223–1232. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou C, Chen G, Huang Y, Zhou J, Lin L,
Feng J, Wang Z, Shu Y, Shi J, Hu Y, et al: Camrelizumab Plus
Carboplatin and Pemetrexed as First-Line Treatment for Advanced
Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial. J
Thorac Oncol. 18:628–639. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang VE, Urisman A, Albacker L, Ali S,
Miller V, Aggarwal R and Jablons D: Checkpoint inhibitor is active
against large cell neuroendocrine carcinoma with high tumor
mutation burden. J Immunother Cancer. 5:752017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qin Y, Yu M, Zhou L, Jiang L and Huang M:
Durable response to combination radiotherapy and immunotherapy in
EP-resistant lung large-cell neuroendocrine carcinoma with B2M and
STK11 mutations: A case report. Immunotherapy. 12:223–227. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sherman S, Rotem O, Shochat T, Zer A,
Moore A and Dudnik E: Efficacy of immune check-point inhibitors
(ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung
Cancer. 143:40–46. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chauhan A, Arnold SM, Kolesar J, Thomas
HE, Evers M and Anthony L: Immune checkpoint inhibitors in large
cell neuroendocrine carcinoma: current status. Oncotarget.
9:14738–14740. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takimoto Sato M, Ikezawa Y, Sato M, Suzuki
A and Kawai Y: Large cell neuroendocrine carcinoma of the lung that
responded to nivolumab: A case report. Mol Clin Oncol. 13:43–47.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oda R, Okuda K, Yamashita Y, Sakane T,
Tatematsu T, Yokota K, Endo K and Nakanishi R: Long-term survivor
of pulmonary combined large cell neuroendocrine carcinoma treated
with nivolumab. Thorac Cancer. 11:2036–2039. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giaj Levra M, Mazieres J, Audigier Valette
C, Molinier O, Planchard D, Frappat V, Ferrer L, Claire Toffart A
and Moro-Sibilot D: Efficacy of immune checkpoint inhibitors in
large cell neuroendocrine lung cancer: Results from a French
Retrospective Cohort: Topic: Drug treatment alone and in
combination with radiotherapy. J Thor Oncol. 12:1556–0864.
2017.
|
|
16
|
Zhang X, Sun Y, Miao Y and Xu S: Immune
checkpoint inhibitor therapy achieved complete response for
drug-sensitive EGFR/ALK mutation-negative metastatic pulmonary
large-cell neuroendocrine carcinoma with high tumor Mutation
Burden: A case report. Onco Targets Ther. 13:8245–8250. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dudnik E, Kareff S, Moskovitz M, Kim C,
Liu SV, Lobachov A, Gottfried T, Urban D, Zer A, Rotem O, et al:
Real-world survival outcomes with immune checkpoint inhibitors in
large-cell neuroendocrine tumors of lung. J Immunother Cancer.
9:e0019992021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Frentzas S, Kwek KY, Konpa A and Jin X:
Efficacy and safety of AK104, an anti-PD-1/CTLA-4 bispecific
antibody, in a patient with large cell neuroendocrine carcinoma of
the lung. J Thor Oncol. 16:5062020. View Article : Google Scholar
|
|
21
|
Wu L, Chen B, Yao W, Li X, Xiao Z, Liu H,
Kong Y, Liu L, Xu Y, Wang Q, et al: A phase Ib/II trial of AK104
(PD-1/CTLA-4 bispecific antibody) in combination with Anlotinib in
advanced NSCLC. Ann Oncol. 32:10062021. View Article : Google Scholar
|
|
22
|
Travis WD, Linnoila RI, Tsokos MG,
Hitchcock CL, Cutler GB Jr, Nieman L, Chrousos G, Pass H and
Doppman J: Neuroendocrine tumors of the lung with proposed criteria
for large-cell neuroendocrine carcinoma. An ultrastructural,
immunohistochemical, and flow cytometric study of 35 cases. Am J
Surg Pathol. 15:529–553. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gazdar AF, Savage TK, Johnson JE, Berns A,
Sage J, Linnoila RI, MacPherson D, McFadden DG, Farago A, Jacks T,
et al: The comparative pathology of genetically engineered mouse
models for neuroendocrine carcinomas of the lung. J Thorac Oncol.
10:553–564. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nicholson AG, Tsao MS, Beasley MB, Borczuk
AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S,
et al: The 2021 WHO Classification of Lung Tumors: Impact of
Advances Since 2015. J Thorac Oncol. 17:362–387. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pang X, Huang Z, Zhong T, Zhang P, Wang
ZM, Xia M and Li B: Cadonilimab, a tetravalent PD-1/CTLA-4
bispecific antibody with trans-binding and enhanced target binding
avidity. MAbs. 15:21807942023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Keam SJ: Cadonilimab: First Approval.
Drugs. 82:1333–1339. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
De Pas TM, Giovannini M, Manzotti M,
Trifirò G, Toffalorio F, Catania C, Spaggiari L, Labianca R and
Barberis M: Large-cell neuroendocrine carcinoma of the lung
harboring EGFR mutation and responding to gefitinib. J Clin Oncol.
29:e819–e822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mauclet C, Duplaquet F, Pirard L, Rondelet
B, Dupont M, Pop-Stanciu C, Vander Borght T, Remmelink M, D'Haene
N, Lambin S, et al: Complete tumor response of a locally advanced
lung large-cell neuroendocrine carcinoma after palliative thoracic
radiotherapy and immunotherapy with nivolumab. Lung Cancer.
128:53–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu S, Qin T, Liu Z, Wang J, Jia Y, Feng
Y, Gao Y and Li K: Anlotinib alters tumor immune microenvironment
by downregulating PD-L1 expression on vascular endothelial cells.
Cell Death Dis. 11:3092020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weichselbaum RR, Liang H, Deng L and Fu
YX: Radiotherapy and immunotherapy: A beneficial liaison? Nat Rev
Clin Oncol. 14:365–379. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Du X, Tang F, Liu M, Su J, Zhang Y, Wu W,
Devenport M, Lazarski CA, Zhang P, Wang X, et al: A reappraisal of
CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res.
28:416–432. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mitsui J, Nishikawa H, Muraoka D, Wang L,
Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, et al:
Two distinct mechanisms of augmented antitumor activity by
modulation of immunostimulatory/inhibitory signals. Clin Cancer
Res. 16:2781–2791. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pentcheva-Hoang T, Simpson TR,
Montalvo-Ortiz W and Allison JP: Cytotoxic T lymphocyte antigen-4
blockade enhances antitumor immunity by stimulating
melanoma-specific T-cell motility. Cancer Immunol Res. 2:970–980.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
He L, Han Q, Zhao M, Ma H, Cheng P, Yang H
and Zhao Y: Case report of radiotherapy combined with anlotinib and
immunotherapy for a patient with esophageal cancer and esophageal
fistula. Appl Radiat Isot. 205:1111622024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Adeoye O and Kozyreva O: Case of
tracheoesophageal fistula formation as a rare complication of
antiangiogenic tyrosine kinase inhibitor therapy for metastatic
hepatocellular carcinoma. Cureus. 15:e417832023.PubMed/NCBI
|
|
36
|
Rekhtman N, Pietanza MC, Hellmann MD,
Naidoo J, Arora A, Won H, Halpenny DF, Wang H, Tian SK, Litvak AM,
et al: Next-Generation sequencing of pulmonary large cell
neuroendocrine carcinoma reveals small cell carcinoma-like and
non-small cell carcinoma-like subsets. Clin Cancer Res.
22:3618–3629. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li
Z, Chen R, Abbas HA, Chang L, Gong Y, et al: The prognostic and
therapeutic role of genomic subtyping by sequencing tumor or
Cell-Free DNA in pulmonary large-cell neuroendocrine carcinoma.
Clin Cancer Res. 26:892–901. 2020. View Article : Google Scholar : PubMed/NCBI
|
